Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - CBRNE - Incendiary Agents, Magnesium and Thermite : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Acute Respiratory Distress Syndrome

Burns, Chemical

Burns, Ocular

Burns, Thermal

CBRNE - Chemical Warfare Agents

Corneal Abrasion

Gas Gangrene

Hazmat




Patient Education
Bioterrorism and Warfare Center

Chemical Warfare

Personal Protective Equipment




Author: Jonathan L Burstein, MD, Assistant Professor of Population and International Health, Harvard School of Public Health; Director and Chair, Section of Disaster Medicine, Division of Emergency Medicine, Harvard Medical School

Jonathan L Burstein is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, Massachusetts Medical Society, National Association of EMS Physicians, and Society for Academic Emergency Medicine

Editors: Mark Keim, MD, Director, Emergency and Disaster Public Health Sciences, Adjunct Assistant Professor, Department of Emergency Medicine, Emory University, National Center for Environmental Health, Centers for Disease Control and Prevention; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Robert G Darling, MD, FACEP, Clinical Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Director, Center for Disaster and Humanitarian Assistance Medicine

Author and Editor Disclosure

Synonyms and related keywords: incendiaries, metal incendiaries, Mg, thermate, thermal burn, incendiary agents, magnesium, thermite, thermal injuries, chemical warfare, magnesium burns, thermite burns, magnesium injury, thermite injury

Background

Two major types of metal incendiaries exist, those that are magnesium based and those of the thermite/thermate type. Most types generally are encountered only in the military or industrial setting.

Magnesium, a silvery white metal of atomic weight 24.32, ignites at 632°C and burns at 1982°C, with magnesium oxide (MgO) as its combustion product. In an exothermic reaction, metallic magnesium can ignite to produce magnesium dihydroxide (ie, Mg(OH)2) and hydrogen. Magnesium is used in either powdered or solid form as an incendiary agent for both illumination and antipersonnel purposes. Various alloys of magnesium (eg, aluminum/zinc/magnesium alloy found in US M126 round) are mechanically sturdier but also can be ignited easily.

Thermite is a mixture of powdered or granular aluminum and powdered iron oxide. When combined with other substances, such as binders, the material is termed a "thermate." All such materials react vigorously when heated to the combustion temperature of aluminum. This reaction produces aluminum oxide, elemental iron, and sufficient heat to melt the iron. The reaction temperature is approximately 2200°C.

Because the burning temperature of these chemicals is so high, standard hazardous-materials clothing (even Level A self-contained and chemical-proof clothing) is not protective.

Pathophysiology

Burning thermite or magnesium produces predominantly thermal injury, but residual particles (especially of magnesium) may produce chemical injury to the eyes, skin, and respiratory tract.

Most injuries are thermal burns, which may be considered identical to deep partial or full-thickness thermal burns (see Burns, Thermal).

Mortality/Morbidity

Outcome of thermite or ignited magnesium burns is essentially the same as for identical thermal burns.



History

The history usually makes the nature of the exposure evident, as the patient or rescuer describes the circumstances leading to exposure to thermite or magnesium incendiaries. In the event that a patient presents with burn injury and is unable to give a history, consider exposure to magnesium, thermite, or other hazardous materials.

Obtain the patient's relevant medical history. In decision making, consider diseases that may affect healing (eg, diabetes mellitus, vascular disease) as well as drug allergies.

Physical

Incendiary agents produce predominantly dermatologic and respiratory effects.

  • Vital signs
    • As with all resuscitations, first priority is to maintain and support airway, breathing, and circulation (ABC). Patients with airway burns or significant fume exposure may require endotracheal intubation and ventilatory support. Acute respiratory distress syndrome (ARDS) may develop.
    • Patients with significant dermal burns require aggressive fluid resuscitation, following a formula such as the Parkland burn resuscitation guidelines, and require monitoring of urinary output and other vital signs.
  • Inhalation of magnesium dust can produce respiratory irritation with the following potential signs and symptoms:
    • Nasal catarrh
    • Productive cough
    • Pneumonitis, including metal fume fever
    • ARDS
    • Hypoxia and tachypnea
    • Airway burns (eg, edema, charring) or lung burns, with potential airway obstruction
    • Wheezes or crackles on lung examination
  • Thermal burns
    • Dermal exposure to incendiary agents produces thermal burns. Thermite burns, being predominantly due to molten iron, essentially are thermal burns with minimally reactive metal particles embedded in the tissue. Assume that these burns are deep partial thickness or full thickness until proven otherwise.
    • Magnesium particle reactions with tissue fluid also may produce magnesium dihydroxide, which produces an alkali chemical burn.
    • Retained magnesium particles in skin may produce a lesion that mimics gas gangrene, with tissue death and intratissue gas bubbles due to hydrogen gas formed from the same reaction.

Causes

Exposure to thermite or burning magnesium likely would occur in the context of military or paramilitary actions (including terrorist activities) or as a result of an industrial or scientific laboratory accident. Exposure potentially could occur as a result of a transportation accident.



Acute Respiratory Distress Syndrome
Burns, Chemical
Burns, Ocular
Burns, Thermal
CBRNE - Chemical Warfare Agents
Corneal Abrasion
Gas Gangrene
Hazmat

Other Problems to be Considered

Metal fume fever



Lab Studies

  • Order lab studies as needed to manage thermal burns and associated lung injury. No specific studies are required for thermite or ignited magnesium exposure.

Imaging Studies

  • Perform chest radiography on patients with possible pulmonary involvement.



Prehospital Care

  • Remove patients from the burning environment, with appropriate attention to personal safety.
  • Flush thermite burns with copious amounts of water and brush or debride them to remove contaminating particles.
  • Initial care for magnesium burn wounds should include removal of all unburned particles by mechanical means, including wound debridement, if needed. If particles are present, do not flush with water until particles have been removed. If water irrigation is needed for burn treatment or other decontamination, use copious amounts to rapidly flush away residual magnesium before the resulting chemical reaction can cause harm.
  • Treat burns with standard thermal burn treatment techniques. Undertake standard support of the ABCs, including intubation and fluid resuscitation if needed.
  • Cover burned areas with dry sterile dressings. Avoid large areas of wet dressings due to the risk of hypothermia.
  • Narcotic analgesia may be useful if the patient's hemodynamic status permits.

Emergency Department Care

  • Institute airway support.
  • Start fluid resuscitation, guided by formulas for similar thermal burns.
  • Perform wound debridement to remove residual particles of magnesium or iron.
  • Aggressively seek and treat associated traumatic injuries (eg, from blast).
  • Institute analgesia.
  • Consider all incendiary burns tetanus prone and administer appropriate tetanus prophylaxis.

Consultations

  • A burn surgeon or other appropriate surgeon (eg, plastics, trauma) should be involved in care.
  • Consult an ophthalmologist if eye injury has occurred.
  • Continuing critical care expertise may be required if injury severity is high.



Major drugs of use are fluids for resuscitation, oxygen for respiratory support, tetanus prophylaxis, and analgesia. Follow standard therapeutic protocols for thermal burn injury. Antibiotic therapy, including topical agents (eg, silver sulfadiazine) and IV or oral agents, may be needed.

Drug Category: Gases

To support respiration and metabolism.

Drug NameOxygen
DescriptionUsed to support respiration and metabolism.
Adult Dose100% oxygen inhaled; reduce to 60% or less as soon as tolerated to minimize oxygen toxicity
Pediatric DoseAdminister as in adults
ContraindicationsCOPD, oxygen toxicity
InteractionsNone reported
PregnancyA - Safe in pregnancy
PrecautionsInspired oxygen concentrations from 50-100% carry a substantial risk of lung damage

Drug Category: Electrolytes

Used to maintain hydration and salt balance.

Drug NameLactated Ringer with normal saline
DescriptionUsually crystalloids such as normal saline or Ringer lactate; little indication for colloid use in acute burn management.
Adult DoseFor resuscitation, 2-4 cm3/kg per percent of TBSA burned to partial thickness or deeper; administer one half of this amount over 8 h and one half over next 16 h; adjust based on central venous pressure, systolic blood pressure, and urine output
Pediatric DoseAdminister as in adults
ContraindicationsMajor complication of isotonic fluid resuscitation is interstitial edema; edema of extremities is unsightly but not a significant complication; edema in brain or lungs is potentially fatal; major contraindication to isotonic fluid resuscitation is pulmonary edema; added fluid promotes more edema and may lead to development of ARDS
InteractionsNone reported
PregnancyA - Safe in pregnancy
PrecautionsIsotonic fluids administered during resuscitation of septic shock require close monitoring of cardiovascular and pulmonary function; stop fluids when desired hemodynamic response is seen or pulmonary edema develops

Drug Category: Topical burn treatment

Topical burn-healing and antimicrobial properties.

Drug NameSilver sulfadiazine (Silvadene)
DescriptionContains both a sulfa antibiotic and a silver ion, which is an antibacterial; speeds burn healing and eases debridement.
Adult DoseTopical application to burned area q12h
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity, G-6-PD deficiency
InteractionsEffect of proteolytic enzymes is reduced when used concomitantly with this product
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCaution in G-6-PD deficiency and renal insufficiency; may cause "tattooing" on the face and should not be used on facial burns in most situations

Drug Category: Topical antibiotics

Antibacterial and to aid in burn healing.

Drug NameBacitracin (AK-Tracin, Baciguent)
DescriptionMild topical antibiotic, usually in an ointment base, for use on facial burns not deep enough to require grafting.
Adult DoseApply topically qid
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity; vaccinia, varicella, epithelial herpes simplex keratitis, mycobacterial infections, and fungal diseases of the eye; patients using steroid combinations after uncomplicated removal of a corneal foreign body
InteractionsNone reported
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsOphthalmic ointments may delay healing of corneal epithelia; in deep-seated eye infections, supplement with systemic medications; prolonged use may result in overgrowth of nonsusceptible organisms

Drug Category: Immunizing agents

Used to immunize patients against tetanus.

Drug NameTetanus toxoid
DescriptionUsed to induce active immunity.
Immunizing agents of choice for most adults and children > 7 y are tetanus and diphtheria toxoids. Necessary to administer booster doses to maintain tetanus immunity throughout life.
Pregnant patients should receive only tetanus toxoid, not a diphtheria antigen-containing product.
In children and adults, may administer into deltoid or midlateral thigh muscles. In infants, preferred site of administration is the mid thigh laterally.
Adult DosePrimary immunization: 0.5 mL IM; give 2 injections 4-8 wk apart and a third dose 6-12 mo after second injection
Booster dose: 0.5 mL q10y
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity; a history of any type of neurologic symptoms or signs following administration of this product; FDA recommends that elective tetanus immunization be deferred during any outbreak of poliomyelitis because tetanus toxoid injections are an important cause of provocative poliomyelitis
InteractionsPatients receiving immunosuppressants, including corticosteroids or radiation therapy, may remain susceptible despite immunization due to poor immune response; cimetidine may enhance or augment delayed-hypersensitivity responses to skin-test antigens; avoid concurrent use of medication with systemic chloramphenicol since it may impair amnestic response to tetanus toxoid; concurrent use of tetanus immune globulin may delay development of active immunity by several days (interaction is nevertheless clinically insignificant and does not preclude concurrent use)
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsDo not use to treat actual tetanus infections or for immediate prophylaxis of unimmunized individuals (use instead tetanus antitoxin, preferably human tetanus immune globulin); diminished antibody response to active immunization may be seen in patients receiving immunosuppressive therapy; better to defer primary diphtheria immunization until immunosuppressive therapy discontinued; routine immunization of symptomatic and asymptomatic HIV-infected persons is recommended

Drug NameTetanus immune globulin (Hyper-Tet)
DescriptionUsed for passive immunization of any person with a wound that may be contaminated with tetanus spores.
Adult DoseProphylaxis: 250-500 U IM in opposite extremity to tetanus toxoid lesion
Clinical tetanus: 3000-10,000 U IM
Pediatric DoseProphylaxis: 250 U IM in opposite extremity to tetanus toxoid
Clinical tetanus: 3000-10,000 U IM
ContraindicationsSince antibodies in globulin preparation may interfere with immune response to vaccination, do not administer within 3 mo of live virus immune globulin administration; may be necessary to revaccinate persons who received immune globulin shortly after live virus vaccination
InteractionsNone reported
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsPersons with isolated IgA deficiency have potential for developing antibodies to IgA and may have anaphylactic reactions to subsequent administration of blood products that contain IgA; do not perform skin testing since intradermal injection of concentrated gamma globulin may cause localized area of inflammation and can be misinterpreted, causing medication to be withheld from a patient not allergic to this material; true allergic responses to human gamma globulin given in prescribed IM manner are extremely rare; do not admix with other medications since usually incompatible



Further Inpatient Care

  • Inpatient care is identical to care for other thermal burns, and it usually involves topical antibiotics (eg, silver sulfadiazine) and surgical debridement. Skin grafting may be needed; institute life-support measures as necessary.

Further Outpatient Care

  • Outpatient care is identical to care for other thermal burns. A physician experienced in burn management usually should provide follow-up care for patients. Treatment may include dressings, topical antibiotics, analgesia, and grafting.

In/Out Patient Meds

  • Medications are standard therapies for thermal burn care and analgesia.

Transfer

  • Transfer patients with thermal burns to a burn center if they meet any of the following burn center criteria:
    • Partial thickness burns over 20% body surface area
    • Full-thickness burns over 10% body surface area
    • Burns involving hands, feet, eyes, ears, and/or perineum
    • Airway involvement
    • Significant underlying illness
    • Age younger than 1 year or older than 65 years

Prognosis

  • Prognosis depends on the extent of the burn injury, the underlying medical history of the victim, and the extent of care available.

Patient Education



Medical/Legal Pitfalls

  • Failure to involve an appropriate burn specialist early in the care of patients with burn wounds may result in poor prognosis and poor functional or cosmetic outcome.
  • Failure to seek associated traumatic injuries (eg, from blast) can lead to significant morbidity or mortality.
  • Failure to investigate underlying conditions or drug allergies.
  • Failure to administer tetanus prophylaxis as needed.
  • Failure to perform adequate fluid resuscitation.

Special Concerns

  • Special concerns mirror those for any burn injury. Patients with poor nutrition, underlying illness retarding healing, immunocompromise, or of extremes of age have a poorer prognosis from such injuries.



  • Curreri PW, Asch MJ, Pruitt BA. The treatment of chemical burns: specialized diagnostic, therapeutic, and prognostic considerations. J Trauma. Aug 1970;10(8):634-42. [Medline].
  • J R Army Med Corps. Chemical casualties. Smokes, fuels, and incendiary materials. J R Army Med Corps. Dec 2002;148(4):395-7. [Medline].
  • Klaasen CD, ed. Casarett and Doull's Toxicology. 6th ed. New York: McGraw Hill;2001.
  • Mendelson JA. Some principles of protection against burns from flame and incendiary munitions. J Trauma. Apr 1971;11(4):286-94. [Medline].
  • Schwartz SI, ed. Principles of Surgery. 7th ed. New York: McGraw Hill;1999.
  • Stewart CE, Sullivan JB, eds. "Military Munitions and Antipersonnel Agents" In: Hazardous Materials Toxicology. 1992;1007-1008.
  • US Department of Transportation. Emergency Response Guidebook. 2000.

CBRNE - Incendiary Agents, Magnesium and Thermite excerpt

Article Last Updated: May 16, 2006